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ABSTRACT. O6-alkylguanine-DNA-alkyltransferase (hAGT) activity provides resistance to 
cancer chemotherapeutic agents and its inhibition enhances chemotherapy. We herein present 
the development of a novel fluorescence assay for the detection of hAGT activity. We designed 
a dsDNA sequence containing a fluorophore-quencher pair, where the fluorophore was attached 
to an 06-benzylguanine. This precursor was synthesized using the Mitsunobu reaction to 
introduce the benzyl group. The alkyl-fluorophore group is transferred to the active site during 
the dealkylation, producing an increase in fluorescence which is correlated to hAGT activity. 
This assay can be used for the evaluation of potential inhibitors of hAGT in a straightforward 
manner. 
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Alkylating agents such as carmustine or temozolamide are chemotherapeutic anticancer 
drugs that produce their cytotoxic effect by generating adducts at multiple sites in DNA.1 The 
most relevant adduct in terms of mutagenesis and carcinogenesis is the alkylation of the O6 
position of guanines.2-9 In particular, the alkylating agent 1,3-bis-(2-chloroethyl)-1-nitrosourea 
(BCNU) initially attacks at the O6 guanine position, causing its cross-link with the opposite 
cytosine, blocking DNA replication and producing G2/M arrest.10, 11 In addition to the well-
known side effects and limitations of chemotherapeutic agents, these substances also show 
acquired tumour resistance problems. The DNA-repair protein human O6-alkylguanine DNA 
alkyltransferase (hAGT or MGMT) is responsible for removing alkyl adducts from the O6 
position of guanines, thereby blocking the cytotoxic effects of the alkylating agents and making 
a crucial contribution to the resistance mechanism.12-14 It is well established that tumoral cells 
show greater expression of this protein, which explains their low sensitivity to chemotherapeutic 
drugs in a large number of cancers.15-17 On the contrary, the promoter methylation of hAGT has 
been associated with patients’ longer survival.18-22 Therefore, pharmacological inhibition of 
hAGT has the potential to enhance the cytotoxicity of a diverse range of anticancer agents.23 
hAGT is a DNA-binding protein that contains a highly conserved internal cysteine, which 
acts as the acceptor site for alkyl groups. It behaves like a suicidal non-enzyme, inactivating 
itself since the S-alkylcysteine formed is not regenerated.24, 25 For this reason, intense research 
effort has been devoted to the identification of small molecules capable of inhibiting hAGT 
activity and significantly enhancing the cytotoxic effect of BCNU in prostate, breast, colon and 
lung tumour cells.23 
Given the potential relevance of hAGT as a prognostic marker of cancer and as a therapeutic 
target, several methods are available to characterize its activity. Moreover, they are also able to 
evaluate the capacity of small molecules for inhibiting hAGT. Most of these methods involve 
radioactivity assays, while others are based on multiple-step enzymatic reactions26-30 or in vivo 
hAGT labeling.31-34 However, the first methods require the use of rigorous safety procedures 
and the others are discontinuous and time-consuming due to the necessity of multiple steps. In 
addition, validation of inhibitors for hAGT activity in vivo needs to consider the cellular uptake 
of these compounds as well as their toxicity per se. Recently, two methods based on the 
conformational change of an intramolecular G-quadruplex were developed by our group.35, 36 
In this paper we describe the development of a one-step FRET assay which improves the 
efficiency of our previous methods because it increases the repair rate of hAGT by using 
double-stranded DNA, the natural substrate of the protein. In addition, the detection of a 
fluorescence increase that is proportional to the repair rate of hAGT represents a low-cost, 
straightforward and rapid method.  
For this purpose, we designed a double-stranded DNA sequence containing a 
fluorophore-quencher pair (Scheme 1). The fluorophore was post-synthetically and covalently 
attached to a modified O6-benzylguanine (FdG) and the quencher was introduced in a very close 
position of the complementary strand of the duplex (QdU-complementary or QdU-mismatch), 
quenching the fluorescence. The fluorophore was transferred together with the benzyl group to 
hAGT’s active site when the protein repaired the DNA, restoring the guanine. The removal of 
the fluorophore brought it apart from the quencher, producing a significant increase in 









Scheme 1. A. Chemical structure of the O6-benzylguanine with the fluorophore covalently 
attached to the alkyl group. B. Chemical structure of the quencher group (Dabcyl), covalently 
attached to a 2’-deoxyuridine. C. Schematic representation of the fluorescence assay. 1) 
Annealing of the two strands containing a fluorophore and a quencher group, with the 
correspondent extinction of fluorescence. 2) hAGT repair activity over the benzylguanine, 
dragging the fluorescein group and significantly increasing fluorescence. 
 
The BzdG oligonucleotide was prepared using the appropriate modified 2’-deoxyguanosine 
phosphoramidite (7) in the automated DNA synthesizer using standard protocols37.  
Derivative 7 was prepared from 2’-deoxyguanosine and the protected N-(4-
(hydroxymethyl)benzyl)-trifluoroacetamide (1) (Scheme 2). Its incorporation at the O6 position 
of the guanine was performed through a Mitsunobu reaction. The guanine amino function was 
protected with a dimethylformamidine protecting group. Finally, the protection and 
functionalization of the two hydroxyl groups were carried out under standard conditions. 
The O6-benzyl-2’-deoxyguanosine-containing oligonucleotide and its complementary strands 
with a quencher group (dabcyl, Q) either at the complementary position or at one nucleotide 
shift were synthesized, purified by HPLC and characterized by MALDI-TOF (see 
Supplementary Data). Subsequently, the fluorescein label (F) was attached to the O6-benzyl-2’-
deoxyguanosine amino group by the fluorescein isothiocyanate (FITC) reaction.38 The DNA 
duplexes, one complementary and the other containing a mismatch due to the positioning of the 
dU-quencher phosphoramidite pairing with the modified FdG, were prepared from the 
fluorophore-quencher pair of oligonucleotides under proper annealing conditions (Table 1). We 
explored to different positions of the quencher group in the complementary sequences to ensure 
the maximal quenching of fluorescence and to minimize steric effects and complementary 
discrepancies. In the case of the first duplex the placement of the quencher in the 
complementary base of the modified guanine provokes a mismatch in the sequence (G:dU) 
instead of a (G:C) pair. The second duplex contained the quencher group at one nucleotide shift 
with respect to the benzyl-2’-deoxyguanosine in the opposite sequence to maintain 
complementarity, expecting that the fluorescence extinction would remain efficient and 
intending to minimize the steric impediments for the repair action of hAGT. 
 
 
Scheme 2. A) Chemical synthesis of the O6-benzyl-2’-deoxyguanosine phosphoramidite. a) 
TEA, EtTFA in DCM, 0ºC to r.t. o/n b) Ac2O, DMAP, TEA in DMF, r.t. 4h; c) Compound 1, 
PPh3, DEAD in Dioxane, r.t. o/n: d) MeOH:NH3 (1:1), 55ºC 4h; e) (CH3O)2CH-N(CH3)2 in 
DMF; f) DMT-Cl, DIEA in Pyr, r.t. o/n; g) DIEA, CNEOP(Cl)N(iPr)2 in DCM, r.t.  
 
 
Table 1. Sequences of the two different duplexes used in this work. 
Name Sequence 
Oligo-FdG: Complementary-QdU 5’-ATC TTC TCFG ATT CA-3’ 
               3’-TAG AAG AGC QdUAA GT-5’ 
Oligo-FdG:Mismatch-QdU          5’-ATC TTC TCFG ATT CA-3’ 
             3’-TAG AAC AGQdU TAA GT-5’ 
 
First, to see the possible effect of these two bulky groups in the duplex formation, its thermal 
stability was studied at 260 and 485 nm and compared to each other (see Table S2 at 
Supplementary Data). In general, we observed destabilization of the duplex at 260 nm in the 
presence of the bulky substituent in the O6 position of the central guanine, compared to the 
controls. However, both duplexes are stable at 30ºC. The duplex structure of both pairs were 
studied by CD spectra at 25ºC confirming that the fluorescein-benzyl substitution did not affect 
the overall secondary structure of the DNA (See Figure S1, SD). In order to be able to use these 
two duplexes in a fluorescence-quenching assay, we studied how the stability of the duplexes 
affects the emission of fluorescence by monitoring the emitted fluorescence at excitation 
wavelength of 485 nm (See Figure S2, SD). Significant differences in the melting temperature 
were observed due to the separation of the fluorophore and the quencher and a great increase in 
the fluorescent signal was detected. In the case of the mismatched sequence, this increase in 
fluorescence is produced at 26ºC while in the fully complementary duplex, the quencher effect 




















Figure 1. HPLC profile of the repair reaction of the FdG double stranded sequence in the 
absence of the quencher group in the complementary strand. The HPLC analysis was performed 
at 37 ºC. 
 
Efficient reaction with hAGT requires the FdG modification to correctly accommodate into 
the active site. This brings the CH2 which is attached at the O6 position in closer proximity to 
the thiol group of Cys145, making the reaction possible. To study the capacity of the 
fluorescein-benzyl group to enter the active site of hAGT without affecting the hAGT activity, 
the reaction was analyzed by HPLC. For this purpose, the full-length hAGT was over-expressed 
and purified as previously described.35, 39 Increasing concentrations of the protein were 
incubated with an excess of the double-stranded FdG sequence for 90 min at 30ºC and analyzed 
using HPLC. The reaction was performed in substoichiometric conditions due to the fact that 
high amount of DNA was required to detect the peak corresponding to the repaired sequence. 
Figure 1 shows one of the HPLC profiles of the reaction’s final products of hAGT at 37ºC. The 
appearance of a peak with a shorter retention time corresponds to the repaired sequence, formed 
by the removal of the fluorescein-benzyl group. Even if the reaction was not quantitative due to 
the lower amount of hAGT used in the experiment, the repair of the alkylguanine indicated that 
hAGT has the capacity to accommodate bulky groups, including a fluorophore, in the active site 
without upsetting its repair activity. This study was performed in the absence and presence of 
the quencher in the complementary strand with similar results. 
We then tested the effectiveness of our proposed fluorescence method to evaluate the repair 
activity of hAGT. We performed the hAGT reaction using a 10 nM concentration of the 
fluorescently-dabcyl labelled duplex for 20 min, using different hAGT concentrations. We 
determined 10 nM to be the minimum amount of double-stranded DNA required to achieve a 
detectable and reliable difference in intensity compared to the background. As expected, the 
fluorophore-quencher pair gave low background fluorescence, because of the quenching effect 
produced by the proximity of these two groups in the base paired sequence. The presence of 
hAGT produced a remarkable increase in fluorescence intensity caused by the transfer of the 
fluorescein-benzyl group to its active site. The increase rate in fluorescence intensity correlated 
directly with the amount of hAGT in the reaction mixture (Figure 2). Moreover, the inactive 
mutant hAGT-C145S did not exhibit any decrease in fluorescence due to its inability to repair 
the alkylated DNA (see Supplementary data).  
In summary, we have described a novel route for the synthesis of an O6-benzyl-2’-
deoxyguanosine precursor which incorporated to an oligonucleotide sequence, can become a 
fluorescently labelled substrate for measuring hAGT repair activity. Annealing with a 
complementary quencher strand produces a duplex with low basal fluorescence. Using this 
labelled oligonucleotide, we have developed a new in vitro assay for the quantification of the 
DNA repair activity of hAGT and the identification of potential inhibitors as chemotherapy 
enhancers. The novelty of this method compared to existing ones 26-33 is the single-step and real-
time measurement of the reaction in vitro, representing a rapid and straightforward method that 
reduces cost, time and effort. In contrast with our previous developed methods to quantify 
hAGT activity,35, 36 this system uses a double-stranded oligonucleotide, which is the natural 
substrate for the hAGT activity, improving efficiency and reliability due to its easy 
quantification of the fluorescence increase upon activity. We believe that this new method will 
facilitate the search for new and more potent inhibitors which enhance the effect of 
chemotherapeutic drugs. However, the thermal stability of the oligonucleotides should be 






















Figure 2. hAGT activity assay. A) Increase of fluorescence with respect to the background 
fluorescence of the oligonucleotide during 20 minutes. B) Total increase of fluorescence after 
20 minutes of reaction with different concentrations of hAGT 
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1. Material and methods 
1.1 Abbreviations: 
Ac: acetyl, Ac2O: acetic anhydride, ACN: acetonitrile, AcOEt: ethyl acetate, anh: anhydrous, 
Ar: aromatic, BCNU: bis-chloroethylnitrosourea, Bz: benzyl, Bzl: benzoyl, CPG: controlled 
pore glass, Dabcyl: dimethylamino-azobenzoic acid, DCM: dichloromethane, DEAD: diethyl 
azodicarboxylate, DIEA: N,N-diisopropylethylamine, DMAP: N,N-dimethylaminopyridine, 
DMF: N,N-dimethylformamide, dmf: dimethylaminomethylidene, DMT: 4,4’-dimethoxytrityl, 
DMT-Cl: 4,4’-dimethoxytrityl chloride, DMSO: dimethylsulfoxide, DTT: dithiothreitol, EtTFA: 
ethyl trifluoroacetate, F: fluorescein, FG: fluorescein-benzylguanosine, FITC: Fluorescein 
isothiocyanate, FRET: fluorescence resonance energy transfer, hAGT: human O6-alkylguanine-
DNA alkyltransferase, LCAA: long chain amino alkyl, MALDI: matrix-assisted laser 
disorption/ionization, MeOH: methanol, PPh3: triphenylphosphine, Pyr: pyridine, QdU: (N-4'-
carboxy-4-(dimethylamino)-azobenzene)-aminohexyl-3-acrylamido]-2'-deoxyuridine, RP-
HPLC: reverse phase high pressure liquid chromatography, TCA: trichloroacetic acid, TEA: 
triethylamine, TEAA: triethylammonium acetate, THAP: trihydroxyacetophenone monohydrate, 
THF: tetrahydrofuran, TLC: thin-layer chromatography, TOF: time of flight, UV: ultraviolet. 
1.2 Chemicals 
Reagents for oligonucleotide synthesis including phosphoramidite monomers of dABzl, dCBzl, 
dGdmf and T, the 5’-deblocking solution (3% TCA in DCM), activator solution (0.4 M 1H-
tetrazole in ACN), CAP A solution (Ac2O /Pyr/THF), oxidizing solution (0.02 M iodine in 
THF/Pyr/water (7:2:1), supports and LCAA-CPG were purchased from Applied Biosystems 
(PEBiosystems Hispania S.A., Spain) and Link Technologies Ltd.(Scotland) and used as 
received. Sephadex G-25 (NAP-10) columns were purchased from GE Healtcare, USA. The 96-
well Optical reaction plates were purchased to Nunc, USA. HiTrapTM FF column were 
purchased at GE Healthcare. FITC (isomer I) and the rest of chemicals were purchased from 
Aldrich, Sigma, or Fluka (Sigma-Aldrich Quimica S.A., Spain), and used without further 
purification. Anhydrous solvents and deuterated solvents (CDCl3, CD3OD and DMSO-d6) were 
obtained from reputable sources and used as received. Thin-layer chromatography (TLC) was 
carried out on aluminium-backed Silica-Gel 60 F254 plates. Column chromatography was 
performed using Silica Gel (60 Å, 230 x 400 mesh).  
1.3. Instrumentation 
Oligonucleotide sequences were synthesized on an Applied Biosystems 3400 DNA Synthesizer 
(Applied Biosystems, USA). RP-HPLC purifications were performed on a Waters 
chromatography system using Nucleosil semi-preparative 120 C18 (250x4 mm) columns. 
Analytical RP-HPLC was performed using a XBridge OST C18 2.5 µm column and a Nucleosil 
Analytical column 120 C18 (250x4mm). Oligonucleotides were quantified by UV absorption at 
260 nm with a Jasco V650 spectrophotometer. Mass spectra were recorded on a MALDI 
Perseptive Voyager DETM RP time-of-flight (TOF) spectrometer (Applied Biosystems, USA) 
equipped with nitrogen laser at 337 nm using a 3ns pulse. The matrix used contained 2,4,6-
trihydroxyacetophenone (THAP, 10 mg/mL in ACN/ water 1:1) and ammonium citrate (50 
mg/mL in water). NMR spectra were measured on Varian Mercury-400. Chemical shifts are 
given in parts per million (ppm); J values are given in hertz (Hz). All spectra were internally 
referenced to the appropriate residual undeuterated solvent. 
UV analyses were performed using a Jasco V-650 instrument equipped with a thermoregulated 
cell holder. Set temperature was controlled with an 89090A Agilent Peltier device and Hellma 
quartz cuvettes were used (1000 µL volume). CD spectra were recorded on a JASCO 
spectropolarimeter J-810. Fluorometric measurements were performed on a JASCO FP6200 
spectrofluorometer at 25ºC and with a Multi-Detection Microplate Reader SpectraMax M5 
(Molecular devices BioNova Scientific, Sunnyvale, USA).  
2. Chemical synthesis of the O6-benzyl-2’-deoxiguanosine phosphoramidite precursor 
2.1. Preparation of N-(4-(hydroxymethyl)benzyl)-trifluoroacetamide (1) 
4-aminomethylbenzylalcohol (500 mg, 2.89 mmol) was dissolved in 3 ml DCM. TEA (3.0 eq, 
1.169 ml, 8.4 mmol) was added dropwise and kept under argon atmosphere. Afterwards, 400 µl 
(1.2 eq, 3.36 mmol) of EtTFA were added dropwise and the mixture was stirred in argon 
atmosphere at room temperature for 4 hr. The reaction was followed up by TLC (DCM:MeOH 
5%). The reaction mixture dissolved in DCM and was washed with brine and the organic phase 
dried with MgSO4. The organic phase was filtered and evaporated. The crude of the reaction 
was purified by chromatography (silica gel), eluted with a gradient of 0-5% MeOH in DCM. 
Yield (1, 500 mg, 76%, white solid). TLC Rf=0.36 (DCM:MeOH 95:5), MS (EI 70 eV) m/z 
calcd for C10H14F3N2O2 (M+ + NH4+) 251.1002 found 251.1002. 
1H-NMR (400 MHz, CDCl3) δ [ppm] 4.52 (d, 2H J=5.8 Hz, Bz-CH2NH), 4.70 (s, 2H, Bz-
CH2O), 6.5 (s, 1H, OH), 7.25 (d, 2H J = 8 Hz, Bz-Harom), 7.37 (d, 2H J = 8 Hz, Bz-Harom). 
13C NMR (100 MHz, CDCl3) δ [ppm] 43.64 (Bz-CH2NH), 64.79 (Bz-CH2O), 115.70 (q, J = 
287.9 Hz, CF3), 127.55 (2Carom), 128.18 (2Carom), 135.16 (Cq-arom), 141.0 (Cq-arom), 157.09 (q, J = 
157.19 Hz, COCF3). 
19F NMR (376 MHz, CDCl3) δ [ppm] -75.84 (COCF3).  
2.2. Preparation of 3’,5’-O-diacetyl-2’-deoxyguanosine (2) 
2’-Deoxyguanosine (1 g, 3.78 mmols, 1 eq.) was dried by coevaporation with anhydrous DMF 
and dissolved in 20 ml of anhydrous DMF. Then, 90 mg of DMAP (0.74 mmols, 0.2 eq.) were 
dissolved in 2 ml of anhydrous DMF and added dropwise. Next, 2.6 mL of TEA (18.5 mmols, 
5.0 eq.) and 1.05 ml of Ac2O (11.1 mmols, 3.0 eq.) were added and the mixture dissolved 
completely. The solution was left to react for 4 hours at r.t. Afterwards cold DCM was added to 
precipitate the desired compound. The mixture was vacuum-filtered and the desired compound 
dried. Yield (2, 1.1 g, 91.6%, white solid). MS (EI 70 eV) m/z calcd for C14H18N5O6 (M+ + H+) 
352.12 found 352.12 
1H-NMR (400 MHz, MeOD) δ [ppm] 1.93 (s, 3H, CH3O), 2.01 (s, 3H, CH3O), 2.47 (m, 1 H, 
2’), 2.91 (m, 1H, 2’’), 4.2 (m, 1 H, 4’), 4.26 (m, 2H, 5’, 5’’), 5.34 (m, 1H, 3’), 6.15 (m, 1H, 1’), 
7.76 (s, 1H, 8). 
2.3. Preparation of O6-(N-4-((hydroxymethyl)benzyl)-trifluoroacetylmide)-3’,5’-O-
diacetyl-2’-deoxyguanosine (3) 
3’,5’-O-diacetyl-deoxyguanosine (2, 620 mg, 1.79 mmol) was dried 3 times by evaporation of 
DMF. PPh3 (1.42 g; 5.4 mmol, 3 eq) and the protected phenol (1, 500 mg, 2.15 mmol, 1,2 eq) 
was added and left under vacuum for 2 h. Then, the mixture was dissolved in anhydrous 
dioxane (10.0 ml) and maintained under an argon atmosphere. Finally, DEAD (860 µl; 5.4 
mmol 3 eq) was added dropwise. The reaction mixture was stirred for 4 hours at room 
temperature and the progress of the reaction was monitored by TLC (DCM:MeOH 9:1). The 
orange reaction was concentrated under vacuum to obtain a viscous oil. The oil was purified by 
flash chromatography using a gradient of MeOH in DCM to yield a white solid (750 mg, 75%). 
TLC Rf=0.42 (DCM:MeOH 9:1), MS (EI 70 eV) m/z calcd for C24H26F3N6O7 (M+ + H+) 567.18 
found 567.181 [M+]. 
1H-NMR (400 MHz, CDCl3) δ [ppm] 2.08 (s, 3H, CH3CO), 2.12 (s, 3H, CH3CO), 2.52 (m, 1H, 
2’), 2.98 (m, 1H, 2’’), 4.33 (m, 2H, 5’,5’’), 4.52 (m, 1H, 4’), 4.90 (s, 2H, Bz-CH2NH), 5.43 (m, 
1H, 3’), 5.55 (s, 2H, Bz-CH2O), 6.28 (dd, 1H, J = 8 Hz, 1’), 7.27 (d, 2H, J = 8 Hz, Bz-Harom), 
7.49 (d, 2H, J = 8 Hz, Bz-Harom), 7.74 (s, 1H, 8). 
13C NMR (100 MHz, CDCl3) δ [ppm] 20.76 (CH3CO), 20.93(CH3CO), 36.69 (C-2’), 43.60 (Bz-
CH2NH), 63.79 (C-5’), 67.51 (Bz-CH2O), 74.61 (C-3’), 82.30 (C-1’), 84.44 (C-4’), 115.85 (q, J 
= 287 Hz, CF3), 116.11 (C-5), 128.06 (2Carom), 128.77 (2Carom), 135.74 (C-8), 136.49 (Cq-arom), 
137.56 (Cq-arom), 153.53 (C-4), 156.63-157.74 (q, J = 37 Hz COCF3), 159.15 (C-2), 160.87 (C-
6), 170.27 (CO), 170.61 (CO). 
19F NMR (376 MHz, CDCl3) δ [ppm] -75.76 (COCF3). 
2.4. Preparation of the deprotected O6-(N-4-((hydroxymethyl)benzyl)-trifluoro-
acetylmide)-2’-deoxyguanosine (4) 
Compound (3) was dissolved in 3 ml of MeOH and transferred to a polypropylene conical tube 
(50 ml) with a stirring bar. Ammonium hydroxide (20%) 3 mL was added and the mixture was 
stirred during 2 hours. The reaction was followed up by TLC. The solvent was evaporated and 
the crude was purified by flash chromatography (DCM:MeOH 95:5 to 90:10), yielding the 
expected compound 4 (112 mg, 46 %, solid). TLC Rf=0.18 (DCM:MeOH 95:5), MS (EI 70 eV) 
m/z calcd for C20H22F3N6O5 (M+ + H+) 483.1598 found 483.1599 [M+]. 
1H-NMR (400 MHz, MeOD) δ [ppm] 2.31 (m, 1H, 2’), 2.75 (m, 1H, 2’’), 3.73 (dd J = 12 Hz, J 
= 3, 1H, 5’), 3.83 (dd J = 12 Hz, J = 3, 1H 5’’), 4.03 (m, 1H, 4’), 4. 43 (s, 2H, Bz-CH2NH2), 
4.54 (m, 1H, 3’), 5.48 (s, 2H, Bz-CH2O), 6.28 (dd, 1H J = 8 Hz, J = 6 Hz, 1’), 7.27 (d, 2H J = 8 
Hz, Bz-Harom), 7.45 (d, 2H J = 8 Hz, Bz-Harom), 8.01 (s, 1H, 8). 
13C NMR (100 MHz, MeOD) δ [ppm] 39.73 (C-2’), 42.58 (Bz-CH2NH), 62.32 (C-5’), 67.25 
(Bz-CH2O), 71.73 (C-3’), 85.39 (C-1’), 88.24 (C-4’), 114.55 (C-5), 116.049 (q J = 286.7 Hz, 
CF3), 127.4 (2Carom), 128.31 (2Carom), 135.91 (C-8), 137.01 (Cq-arom), 138.65 (Cq-arom), 152.87 
(C-4), 157.54 (q, J = 37 Hz COCF3), 159.9 (C-2), 160.66 (C-6). 
19F-NMR (376 MHz, MeOD): δ [ppm] -77.20 (CF3) 
2.5. Preparation of the N2-(N’,N’-dimethylamino)methylen)-O6-(N-4-((hydroxymethyl)-
benzyl)-trifluoroacetylamide)-2’-deoxyguanosine (5) 
The product (4, 0.23 mmol) was dried by evaporation with anhydrous DMF and dissolved in 2 
ml of DMF under argon. Dmf protecting group 125 µL (4 eq, 0.93 mmol) was added and the 
mixture was stirred during 4 hours. The reaction was followed by TLC. The solvent was 
evaporated and crude was purified by flash chromatography over silica gel yielding the 
expected compound 5 (112 mg, 46 %, solid). TLC Rf=0.28 (DCM:MeOH 90:10), MS (EI 70 
eV) m/z for C23H27F3N7O5 (M+ + H+) 538.202 found 538.2017 [M+]. 
1H-NMR (400 MHz, MeOD) δ [ppm] 2.39 (m, 1H, 2’), 2.76 (m, 1H, 2’’), 3.08 (s, 3H, N(CH3)2), 
3.14 (s, 3H, N(CH3)2), 3.73 (dd J = 12 Hz, J = 3, 1H, 5’), 3,79 (dd J = 12 Hz, J = 3, 1H 5’’), 
4.01 (m, 1H, 4’), 4.43 (s, 2H, Bz-CH2NH), 4.56 (m, 1H, 3’), 5.57 (s, 2H, Bz-CH2O), 6.41 (dd, 
1H J = 8 Hz, J = 6 Hz, 1’), 7.29 (d, 2H J = 8 Hz, Bz-Harom), 7.48 (d, 2H J = 8 Hz, Bz-Harom), 
8.24 (s, 1H, 8), 8.65 (s, 1H, CH=N). 
13C NMR (100 MHz, MeOD) δ [ppm] 34.58 (C-2’), 40.62, 40.73 (2C, N(CH3)2), 43.14 (Bz-
CH2NH2), 62.54 (C-5’), 68.02 (Bz-CH2O), 71.88 (C-3’), 85.38 (C-1’), 88.63 (C-4’), 116.77 (q J 
= 286.7 Hz, CF3), 117.60 (C-5), 128.01 (2Carom), 128.56 (2Carom), 136.77 (C-8), 137.57 (Cq-arom), 
140.62 (Cq-arom), 153.42 (C-4), 158.94 (q, J = 37 Hz COCF3), 159.6 (C-2), 160.41 (C-6), 162.60 
(CH=N). 
19F-NMR (376 MHz, MeOD): δ [ppm] -77.16 (CF3). 
2.6. Preparation of 5’-O-(4,4’-dimethoxytrityl)-[N2-(N,N’-dimethylamino)-O6-(N-4-
((hydroxymethyl)benzyl)-trifluoroacetylmide)-2’-deoxyguanosine (6) 
A solution of (90 mg, 167 µmols) of product (5) was dried three times with anhydrous pyridine 
(3  5 mL) and finally dissolved in anh. pyr (4 ml) and placed under argon. Then, 125 mg (1.4 
eq, 0.32 mmols) of DMT-Cl and 14 mg (0.5 eq, 0.115 mmols) of DMAP were added. The 
reaction was stirred under argon over night at room temperature and protected from the light. 
The product formation was followed up by TLC. Then, the reaction was quenched with 1 ml of 
MeOH and the solvent was evaporated. The crude product was purified by flash 
chromatography over silica gel (DCM 100%, DCM:MeOH 1-10% + 2% Et3N) to give 117 mg 
(83%, solid) of compound 6. TLC Rf=0.68 (DCM:MeOH 95:5). 
1H-NMR (400 MHz, CDCl3) δ [ppm] 2.49 (m, 1H, 2’), 2.65 (m, 1H, 2’’), 2.92 (s, 6H, N(CH3)2), 
3,41 (m, 2H, 5’ 5’’), 3.66 (s, 6H, DMT-O-CH3), 4.14 (m, 1H, 4’), 4.40 (s, 2H, Bz-CH2NH), 4.58 
(m, 1H, 3’), 5.44 (s, 2H, Bz-CH2O), 6.33 (t, 1H J = 6 Hz, 1’), 6.66 (d, 2H J = 8 Hz, DMT-
Harom), 6.68 (d, 2H J = 8 Hz, DMT-Harom), 7.06-7.34 (m, 13H DMT-Harom, Bz-Harom), 7.87 (s, 1H, 
8), 9.32 (s, 1H, N=CH). 
19F-NMR (376 MHz, CDCl3): δ [ppm] -75.56 (CF3). 
2.7. Preparation of 5’-O-(4,4’-dimethoxytrityl)-[N2-(N,N’-dimethylamino)-O6-(N-4-
((hydroxymethyl)benzyl)-trifluoroacetylmide)-2’-deoxyguanosine-3’-O-(N,N-diisopropyl-
2-cyanoethyl phosphoramidite (7) 
A solution of product (6) (117 mg, 136 µmols) was dissolved in anhydrous CH2Cl2 under argon 
and at 0ºC. Then, DIPEA (95 µL, 540 µmol, 4 eq) and 2-cyanoethyl 
diisopropylphosphoramidochloride (50 µL, 204 µmol) were added. After 15 min the reaction 
was allowed to reach r.t and stirred for 1 hour. The reaction was quenched with brine, extracted 
with CH2Cl2, dried (MgSO4) and concentrated. The resulting oil was used directly without 
further purification for oligonucleotide synthesis. TLC Rf=0.68 (hexane/EtOAc 20:70 + + 2% 
Et3N). 
 
1H-NMR (400 MHz, CDC3) δ [ppm] 1.25 (s, 6H, NCH(CH3)2), 1.26 (s, 6H, NCH(CH3)2), 2.50 
(m, 1H, 2’), 2.65 (m, 3H, 2’’, CH2CN), 2.92 (s, 6H, N(CH3)2), 3.24 (m, 2H, 5’ 5’’), 3.41 (m, 4H, 
CH2CH2OP, NCH(CH3)2), 3.66 (s, 6H, DMT-O-CH3), 4.14 (m, 1H, 4’), 4.42 (s, 2H, Bz-
CH2NH), 4.58 (m, 1H, 3’), 5.54 (s, 2H, Bz-CH2O), 6.33 (t, 1H J = 6 Hz, 1’), 6.65 (dd, 4H J = 7 
Hz, DMT-Harom), 7.06-7.34 (m, 13H DMT-Harom, Bz-Harom), 7.87 (s, 1H, 8), 9.32 (s, 1H, CH=N). 
13C NMR (100 MHz, MeOD) δ [ppm] 20.45 (CH2CN), 24.47, 24.52, 24.54, 24.59 (4C, P-
NCH(CH3)2), 39.28 (C-2’), 43.18 (2C, N(CH3)2), 43.31 (2C, C(CH3)2), 43.55 (Bz-CH2NH2), 
55.16 (2C, DMT-OCH3), 57.94 (CH2CH2OP), 63.48 (C-5’), 68.31 (Bz-CH2O), 74.38 (C-3’), 
84.59 (C-1’), 85.80 (C-4’), 86.43 (DMT-Cq), 113.11 (4C, DMT-C3), 117.46 (CF3), 117.69 
(CN), 119.15 (C-5), 127.28 (2C, Carom), 128.05 (2C, Carom), 128.18, 128.72, 129.93, 129.95 (9C, 
DMT-C3-arom), 135.05 (2C, DMT-Cq-arom), 135.56 (Bz-Cq-arom), 135.97 (C-8), 140.12 (Bz-CqArom), 
140.70 (DMT-CqArom), 151.45 (2C, DMT-CqArom), 152.50 (C-4), 158.47 (2C, COCF3, C-2), 
160.57 (C-6), 162.56 (N=CH). 
19F-NMR (376 MHz, CDCl3): δ [ppm] -75.56 (CF3). 
31P-NMR (161 MHz, CDCl3): δ [ppm] 148.83. 
3. Synthesis and purification of oligonucleotides 
3.1. Oligonucleotide synthesis 
The oligonucleotide sequences were synthesized at 1 µmol scale using the standard protocols 
(Table 1). The incorporation of the O6-(N-4-((hydroxymethyl)benzyl)-trifluoroacetylmide)-2’-
deoxyguanosinephosphoramidite (BzdG) in the sequence was carried out manually with a 
coupling time of 15 min, obtaining a yield of 75%. The incorporation of the QdU-nucleobases to 
the complementary sequences was automatically performed on the synthesizer. In all the 
syntheses we used dimethylformamidino-protected guanine phosphoramidite (7). The syntheses 
were completed using the DMT-OFF protocol, except for the sequence containing BzdG, which 
was synthesized in DMT-ON mode to help with the purification. 
3.2. Oligonucleotides deprotection and purification.  
After oligonucleotide synthesis, the solid supports were transferred to screw-cap vials and 
incubated with a solution of concentrated aqueous ammonia overnight at room temperature, and 
additional 15 min incubation at 55ºC were needed for the sequence containing BzdG. The 
solutions were then filtered using sterile cotton and transferred into a 2 mL eppendorf tube. The 
solutions were evaporated using a nitrogen system to remove the ammonia. The resulting 
products were desalted by Sephadex G-25 using water as eluent.  
The sequence containing BzdG was purified by reversed-phase HPLC using the DMT-ON 
protocol in a Nucleosil 120 10-C18 10 µm (250x8 mm) column with a flow rate of 3 mL/min 
and an increasing gradient of ACN (15% to 80%) over 0.1 M aqueous TEAA pH 6.5, during 20 
minutes. The retention time for the oligonucleotide was 10.23 min. The pure fractions were 
combined and evaporated to dryness. The obtained residues were detritylated by adding 1 mL of 
80% acetic acid solution for 30 min at room temperature. The deprotected oligonucleotides were 
desalted and further purified by a second round of chromatography, using the DMT-OFF 
protocol: 20 minutes of linear gradient from 5% to 50% ACN over 0.1 M aqueous TEAA pH 
6.5. The yield and purity obtained for the products was around 85% in all cases. The length and 
homogeneity of the oligonucleotide were verified by MALDI-TOF (table 1).  
The DNA-strand concentration was determined by absorbance measurements (260 nm) and its 
extinction coefficients. Oligonucleotide samples were kept at 4 ºC until further use.  
3.3. Preparation of the fluorescent FdG oligonucleotide.  
The 5’-ATCTTCTCBzGATTCA-3’ oligonucleotide was left to react with fluorescein 
isothiocyanate (FITC) through its free amino group as follows. 5 O.D. of the oligonucleotide 
were dissolved in 250 µL of an aqueous solution of 0.2 M NaHCO3 (pH 9) and 10 eq of a 
solution of FITC solved in 250 µL DMF were added and left to react at rt for 8h. Then, 100 µL 
of an aqueous solution of 0.2 M NaHCO3 (pH 9) and an additional 10 equiv of FITC in 100 µL 
of DMF were added and the mixture was left to react overnight at rt. The mixtures were 
concentrated to dryness and the residue resuspended in 1 mL of water. The solution was 
purified by Sephadex G-25 and analyzed by RP-HPLC using an XBridge OST C18 2.5 µm 
column. The coupling efficiency was determined by HPLC analysis (86 %). The purified 
oligomers were analyzed by MS (MALDI-TOF), see table 1. 
DNA duplexes were obtained by annealing equimolar concentrations of the control, BzdG and 
FdG sequences with the complementary oligonucleotide strands at 72 ºC for 5 min and then 
allowing them to slowly cool down to room temperature. 
4. hAGT expression and purification 
In vitro assays were carried out using recombinant hAGT, overexpressed and purified as 
previously described.13 Briefly, hAGT protein was expressed in the E. coli strain Rosetta, 
induced by adding 1 mM IPTG and left to express for 4 h at 30 °C. The pellet was disrupted by 
sonication and centrifuged. The supernatant was filtered, loaded into a HiTrapTM FF column 
and eluted with an Imidazole gradient (20-500 mM) in the following buffer of 350 mM NaCl, 
20 mM Tris pH 8, and 1 mM BME. Finally, the protein was loaded into a Superdex 75 16/60 
being the buffer 200 mM NaCl, 20 mM Tris pH 8.0, 10 mM DTT and 0.1 mM EDTA. The 
protein was concentrated to 2 mg/ml in this buffer and kept at -20 °C in the presence of 40 % 
glycerol. The same protocol was used for the purification of the inactive mutant hAGT-C145S 
expressed in the E. coli strain BL21. This mutant was used as negative control in many 
experiments. 
5. Thermal denaturation studies. 
Melting curves of all the possible pairs of complementary oligonucleotides were measured by 
monitoring the absorbance hyperchromicity at 260 nm. The sample was heated over the range 8-
80 ºC at a heating rate of 1ºC/min. The buffer solution used was 10 mM sodium phosphate pH 
7.0 and 100 mM NaCl. Sample concentration was around 4 µM. Each sample was allowed to 
equilibrate at the initial temperature for 5 min before the melting experiment began. The melting 
temperatures (Tm) are the average value of at least one pair of experiments. The data were 
analyzed by the denaturation curve processing program, MeltWin v. 3.0. Melting temperatures 
(Tm) were determined by computer fitting of the first derivative of absorbance with respect to 
1/T. 
6. Circular Dichroism 
The CD spectra of all the possible pairs of complementary oligonucleotides were registered at 
25ºC over a range of 220–320 nm, with a scanning speed of 50 nm·min−1, a response time of 
4s, data pitch of 0.5 nm, and a bandwidth of 1nm. The duplexes concentration was 2 µM in a 
buffer solutions of 10 mM sodium phosphate pH 7.0 and 100 mM NaCl. The samples were 
annealed before recording of spectra. 
7. HPLC analysis of hAGT dealkylation.  
In order to measure the dealkylation of FdG, 142 pmol and 350 pmol of the duplexes were 
incubated with 40 pmol of full-length-hAGT to a final volume of 400 µl in a reaction buffer 
(200 mM NaCl, 50 mM Tris pH 8.0, 1 mM DTT, 5 mM EDTA). The reaction was incubated for 
90 min at 25ºC and stopped by heating the samples at 72 ºC for 5 min. The reaction products 
were analyzed by HPLC on a Nucleosil analytical column at 60ºC to facilitate the duplex 
dissociation. The HPLC flow rate was 1 ml/min, and a gradient of 10–40% acetonitrile in 20 
min was used. 
8. Fluorescence assay for hAGT activity. 
The fluorescence assay was performed with full-length hAGT and the hAGT-C145S (inactive 
mutant) was used as a negative control. The reaction was accomplished in a total volume of 50 
µl in each well, incubating increasing concentrations of hAGT (50, 100 and 200 nM) in reaction 
buffer (200 mM NaCl, 50 mM Tris pH 8.0, 1 mM DTT, 5 mM EDTA, 20 mM KCl) at 25ºC. 
The assay was initiated by the addition of 5 µl of fluorophore-quencher duplex substrate (10 
nM, 0.5 pmol) and this solution was then placed in a microplate reader system. Fluorescence 
was measured every minute for 20 min at excitation and emission wavelengths of 485 and 535 
nm, respectively. Averages over three readings were taken for each condition tested. Each 
experiment was performed in triplicates. 
Both duplexes were used to measure hAGT repair activity. However, the Oligo-FdG: C QdU 
duplex showed a higher increase in fluorescence relative to the Oligo-FdG:Mismatch-QdU 
duplex, and was used for all experiments.  
Table S1: Sequence of oligonucleotides and its characterization by MALDI-TOF 
Name Sequence Mass found (expected) 
Oligo-BzdG 5’-ATC TTC TCBzG  ATT CA-3’ 4310.9 (expected 4306,94) 
Oligo-FdG 5’-ATC TTC TCFG  ATT CA-3’  4702.2 (expected 4695.31) 
Control  5’-ATC TTC TCG ATT CA-3’ 4190.0 (expected 4187.77) 
Complementary 5’-TGA ATC GAG AAG AT-3’ 4333.8 (expected 4332.77) 
Complementary-QdU 5’-TGA AQdUC GAG AAG AT-3’ 4741.2 (expected 4740.38) 
Mismatch-T 5’-TGA ATT GAG AAG AT-3’ 4348.2 (expected 4347.77) 
Mismatch-QdU 5’-TGA ATQdU GAG AAG AT-3’ 4757.0 (expected 4755.39) 
Sequences of the oligonucleotides used in the development of the hAGT fluorescence assay. 
BzdG represents O6-benzyl-2’-deoxyguanosine. FdG corresponds to the O6- Fluorescein-benzyl-
2’-deoxyguanosine, where fluorescein is a fluorophore group. QdU represents a modified T with 
the quencher group (Dabcyl). Mass spectrometry analysis (MALDI-TOF) and expected mass. 
Table S2. Melting temperatures of the duplexes. 
5’
-ATCTTCTC XA TTCA-3’ 
3’
-TAGAAGA ZW TAAGT-3’ 
 
Name XA ZW Tm (260 nm) 
Control:Complementary GA CT 54.6 
Control: Mismatch-T GA TT 45.0 
Oligo-BzdG:Complementary BzGA CT 33.3 
Oligo-BzdG:Mismatch-T BzGA TT 36.4 
Oligo-BzdG:Mismatch-QdU BzGA QdUT 40.2 
Oligo-BzdG: CQdU BzGA CQdU 41.3 
Oligo-FdG:Complementary FGA CT 33.0 
Oligo-FdG: C QdU FGA CQdU 30.3 
Oligo-FdG:Mismatch-T FGA TT 27.9 
Oligo-FdG:Mismatch-QdU FGA QdUT 34.3 
nd: not determined. 
 
Figure S1: CD spectra of the different duplexes. A) CD spectra of complementary duplexes. 
B) CD of the mismatch duplexes. All the experiments were performed at 25ºC in 10 mM 
sodium phosphate pH 7.0 and 100 mM NaCl with a 2 µM concentration of duplexes.  
 
 
Figure S2: Denaturation curves of duplexes Oligo-FdG:Mismatch-QdU and Oligo-FdG: C 
QdU at 260 nm. All the experiments were performed in 10 mM sodium phosphate pH 7.0 and 








Figure S3: HPLC profiles of the control sequences. A) Mixture of the unmodified dG 
oligonucleotide sequence with its complementary strand (Control:Complementary). B) Mixture 
of the fluorescein-benzyl-modified oligonucleotide sequence with its complementary strand. 




Figure S4: Control experiments of the fluorescence assay. The background fluorescence of 
the double stranded sequence is observed in the absence of hAGT and in the presence of an 
inactive mutant. An increase of fluorescence is only observed in the presence of the same 
concentration of active hAGT (150 nM). The reactions were performed in reaction buffer (200 










Figure S5. Kinetic data of figure 2 (main text). The emission of fluorescence corresponding 
to 3 concentrations of hAGT (10, 20 and 30 nM) is measured for 20 minutes. The reactions 
were performed in reaction buffer (200 mM NaCl, 50 mM Tris pH 8.0, 1 mM DTT, 5 mM 
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